There are many potential entry points to the molecular diagnostics business: biomarker discovery, laboratory operations, instrumentation development, even disease management. Companies in these various sectors are customizing their own approaches to molecular diagnostics and personalized medicines, combining M&A, licensing, and internal R&D to develop what they believe are core opportunities. ( See "Leveraging Assay Platforms to Create Category-Killer Diagnostic Tests," IN VIVO , December 2009 Also see "Leveraging Assay Platforms to Create Category-Killer Diagnostic Tests " - In Vivo, 1 December, 2009. and "Molecular Diagnostics – From Tools to Tests," IN VIVO , May 2006 Also see "Molecular Diagnostics--From Tools to Tests" - In Vivo, 1 May, 2006..)
Taking Stock Of Qiagen
Since its acquisition of Digene in 2007, Qiagen's business mix has shifted significantly towards molecular diagnostics even as the company remains true to its founding premise of making things simpler for customers. It has broadened its skill set in nucleic acid analysis with multiple acquired and licensed technologies for platform development while focusing on high volume tests in women's health and infectious diseases and new ties with pharma. Expect its acquisition pattern to continue.
More from Business Strategy
More from In Vivo
AI-related deal activitiy in the first quarter of 2025 was punctuated by a last-minute $600m raise for Isomorphic Labs.
The process of manufacturing medicines can often be complex, expensive and harmful to the environment. Initiatives like RESILIENCE UK are seeking to simplify this process, utilizing VR technology to create a more sustainable learning environment for both students and companies.
Lundbeck CEO Charl van Zyl spoke with In Vivo about the Danish company’s multipronged transformation, one that involves a rethink of company culture, pipeline strategy and a sharpened focus on innovation in rare neurological disorders.